Allovir Appoints New Chief Medical Officer
Ticker: KLRS · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Allovir just hired a new CMO, Dr. Apelian, who helped get Kadmon's drug approved. Big move for their pipeline.
AI Summary
Allovir, Inc. announced on December 19, 2024, the appointment of Dr. David M. Apelian as Chief Medical Officer. Dr. Apelian previously served as Executive Vice President and Chief Medical Officer at Kadmon Pharmaceuticals, where he played a key role in the development and approval of Tesvla (Inmazeb).
Why It Matters
The appointment of a new Chief Medical Officer with a strong track record in drug development and regulatory approval could signal a renewed focus on pipeline advancement and potential future successes for Allovir.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty, but also potential for positive change in strategy and execution.
Key Players & Entities
- Allovir, Inc. (company) — Registrant
- Dr. David M. Apelian (person) — Newly appointed Chief Medical Officer
- Kadmon Pharmaceuticals (company) — Previous employer of Dr. Apelian
- Tesvla (Inmazeb) (drug) — Drug developed under Dr. Apelian's leadership
FAQ
When was Dr. David M. Apelian appointed as Chief Medical Officer of Allovir, Inc.?
Dr. David M. Apelian was appointed as Chief Medical Officer of Allovir, Inc. on December 19, 2024.
What was Dr. Apelian's previous role before joining Allovir?
Before joining Allovir, Dr. Apelian served as Executive Vice President and Chief Medical Officer at Kadmon Pharmaceuticals.
What significant achievement is Dr. Apelian credited with at Kadmon Pharmaceuticals?
Dr. Apelian is credited with playing a key role in the development and approval of Tesvla (Inmazeb) at Kadmon Pharmaceuticals.
What is Allovir, Inc.'s primary business?
Allovir, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.
Where is Allovir, Inc. headquartered?
Allovir, Inc. is headquartered at 1100 Winter Street, Waltham, MA 02451.
Filing Stats: 1,031 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-12-20 16:21:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALVR The Nasdaq
- $100,000 — rrent year, (iii) a lump sum payment of $100,000 for completion of the proposed merger b
Filing Documents
- d905140d8k.htm (8-K) — 30KB
- d905140dex101.htm (EX-10.1) — 33KB
- 0001193125-24-283140.txt ( ) — 197KB
- alvr-20241219.xsd (EX-101.SCH) — 3KB
- alvr-20241219_lab.xml (EX-101.LAB) — 18KB
- alvr-20241219_pre.xml (EX-101.PRE) — 11KB
- d905140d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit Number Description 10.1 Separation and Release Agreement, dated as of December 19, 2024, by and between AlloVir, Inc. and Diana Brainard. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AlloVir, Inc. Date: December 20, 2024 By: /s/ Edward Miller Name: Edward Miller Title: General Counsel